KAKEN PHARMACEUTICAL CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,410 JPY | +0.62% |
|
-0.06% | +1.70% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company is one of the best yield companies with high dividend expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +1.70% | 825M | - | ||
| +24.17% | 556B | B | ||
| -6.33% | 354B | C+ | ||
| +19.90% | 331B | B- | ||
| +7.95% | 296B | C+ | ||
| +13.45% | 233B | B+ | ||
| +6.04% | 201B | B- | ||
| -10.51% | 193B | A+ | ||
| -12.26% | 143B | C+ | ||
| -6.47% | 144B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4521 Stock
- Ratings Kaken Pharmaceutical Co., Ltd.
